;PMID: 12007509
;source_file_700.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:35..126] = [t:35..126]
;2)section:[e:130..267] = [t:130..267]
;3)section:[e:271..388] = [t:271..388]
;4)sentence:[e:392..565] = [t:392..565]
;5)sentence:[e:566..604] = [t:566..604]
;6)sentence:[e:605..668] = [t:605..668]
;7)sentence:[e:669..771] = [t:669..771]
;8)sentence:[e:772..909] = [t:772..909]
;9)sentence:[e:910..963] = [t:910..963]
;10)sentence:[e:964..1202] = [t:964..1202]
;11)sentence:[e:1203..1265] = [t:1203..1265]
;12)sentence:[e:1266..1414] = [t:1266..1414]
;13)sentence:[e:1415..1591] = [t:1415..1591]
;14)section:[e:1595..1640] = [t:1595..1640]

;section 0 Span:0..30
;Leuk Res  2002 Jun;26(6):601-6
(SEC
  (FRAG (NNP:[0..4] Leuk) (NNP:[5..8] Res) (CD:[10..14] 2002)
        (CD:[15..22] Jun;26-LRB-) (CD:[22..24] 6-RRB-) (CD:[24..28] :601)
        (::[28..29] -) (CD:[29..30] 6)))

;sentence 1 Span:35..126
;A case of smouldering mastocytosis with peripheral blood eosinophilia and 
;lymphadenopathy.
;[45..69]:malignancy:"smouldering mastocytosis"
(SENT
  (NP-HLN
    (NP (DT:[35..36] A) (NN:[37..41] case))
    (PP (IN:[42..44] of)
      (NP
        (NP (VBG:[45..56] smouldering) (NN:[57..69] mastocytosis))
        (PP (IN:[70..74] with)
          (NP
            (NP
              (NML (JJ:[75..85] peripheral) (NN:[86..91] blood))
              (NN:[92..104] eosinophilia))
            (CC:[105..108] and)
            (NP (NN:[110..125] lymphadenopathy))))))
    (.:[125..126] .)))

;section 2 Span:130..267
;Hauswirth AW, Sperr WR, Ghannadan M, Schernthaner GH, Jordan JH,
;Fritsche-Polanz  R, Simonitsch-Klupp I, Fodinger M, Lechner K, Valent P.
(SEC
  (FRAG (NNP:[130..139] Hauswirth) (NNP:[140..142] AW) (,:[142..143] ,)
        (NNP:[144..149] Sperr) (NNP:[150..152] WR) (,:[152..153] ,)
        (NNP:[154..163] Ghannadan) (NNP:[164..166] M,)
        (NNP:[167..179] Schernthaner) (NNP:[180..182] GH) (,:[182..183] ,)
        (NNP:[184..190] Jordan) (NNP:[191..193] JH) (,:[193..194] ,)
        (NNP:[195..203] Fritsche) (::[203..204] -) (NNP:[204..210] Polanz)
        (NNP:[212..214] R,) (NNP:[215..225] Simonitsch) (::[225..226] -)
        (``:[226..231] Klupp) (PRP:[232..233] I) (VBP:[233..234] ,)
        (DT:[235..243] Fodinger) (NNP:[244..246] M,) (NNP:[247..254] Lechner)
        (NNP:[255..256] K) (,:[256..257] ,) (NNP:[258..264] Valent)
        (NNP:[265..267] P.)))

;section 3 Span:271..388
;Department of Internal Medicine I, Division of Hematology and Hemostaseology,
; University of Vienna, Vienna, Austria.
(SEC
  (FRAG (NNP:[271..281] Department) (IN:[282..284] of) (NNP:[285..293] Internal)
        (NNP:[294..302] Medicine) (NNP:[303..304] I) (NNP:[304..305] ,)
        (NNP:[306..314] Division) (IN:[315..317] of) (NNP:[318..328] Hematology)
        (CC:[329..332] and) (NNP:[333..347] Hemostaseology) (,:[347..348] ,)
        (NNP:[350..360] University) (IN:[361..363] of) (NNP:[364..370] Vienna)
        (,:[370..371] ,) (NNP:[372..378] Vienna) (,:[378..379] ,)
        (NNP:[380..387] Austria) (.:[387..388] .)))

;sentence 4 Span:392..565
;Systemic mastocytosis (SM) is a clonal hematologic disease showing abnormal 
;growth and accumulation of mast cells (MC) in visceral organs with or without
; skin involvement.
;[392..413]:malignancy:"Systemic mastocytosis"
;[415..417]:malignancy:"SM"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[392..400] Systemic) (NN:[401..413] mastocytosis))
      (NP (-LRB-:[414..415] -LRB-) (NN:[415..417] SM) (-RRB-:[417..418] -RRB-)))
    (VP (VBZ:[419..421] is)
      (NP-PRD
        (NP (DT:[422..423] a) (JJ:[424..430] clonal) (JJ:[431..442] hematologic)
            (NN:[443..450] disease))
        (VP (VBG:[451..458] showing)
          (NP
            (NP (JJ:[459..467] abnormal) (NN:[469..475] growth))
            (CC:[476..479] and)
            (NP
              (NP (NN:[480..492] accumulation))
              (PP (IN:[493..495] of)
                (NP
                  (NP (NN:[496..500] mast) (NNS:[501..506] cells))
                  (NP (-LRB-:[507..508] -LRB-) (NN:[508..510] MC)
                      (-RRB-:[510..511] -RRB-))))
              (PP-LOC (IN:[512..514] in)
                (NP (JJ:[515..523] visceral) (NNS:[524..530] organs)))
              (PP (IN:[531..535] with) (CC:[536..538] or)
                  (IN:[539..546] without)
                (NP (NN:[548..552] skin) (NN:[553..564] involvement))))))))
    (.:[564..565] .)))

;sentence 5 Span:566..604
;The clinical course in SM is variable.
;[589..591]:malignancy:"SM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[566..569] The) (JJ:[570..578] clinical) (NN:[579..585] course))
      (PP (IN:[586..588] in)
        (NP (NN:[589..591] SM))))
    (VP (VBZ:[592..594] is)
      (ADJP-PRD (JJ:[595..603] variable)))
    (.:[603..604] .)))

;sentence 6 Span:605..668
;In fact, indolent and  aggressive variants have been described.
;[614..622]:malignancy:"indolent"
;[628..647]:malignancy:"aggressive variants"
(SENT
  (S
    (PP (IN:[605..607] In)
      (NP (NN:[608..612] fact)))
    (,:[612..613] ,)
    (NP-SBJ-2
      (NP (JJ:[614..622] indolent)
        (NML-1 (-NONE-:[622..622] *P*)))
      (CC:[623..626] and)
      (NP (JJ:[628..638] aggressive)
        (NML-1 (NNS:[639..647] variants))))
    (VP (VBP:[648..652] have)
      (VP (VBN:[653..657] been)
        (VP (VBN:[658..667] described)
          (NP-2 (-NONE-:[667..667] *)))))
    (.:[667..668] .)))

;sentence 7 Span:669..771
;In addition, SM patients may acquire an  associated hematologic clonal non-MC
;lineage disease (AHNMD).
;[682..684]:malignancy:"SM"
;[710..762]:malignancy:"associated hematologic clonal non-MC lineage disease"
;[764..769]:malignancy:"AHNMD"
(SENT
  (S
    (PP (IN:[669..671] In)
      (NP (NN:[672..680] addition)))
    (,:[680..681] ,)
    (NP-SBJ (NN:[682..684] SM) (NNS:[685..693] patients))
    (VP (MD:[694..697] may)
      (VP (VB:[698..705] acquire)
        (NP
          (NP (DT:[706..708] an)
             (VBN:[710..720] associated) (JJ:[721..732] hematologic)
             (JJ:[733..739] clonal)
            (NML (AFX:[740..743] non) (HYPH:[743..744] -)
              (NML (NN:[744..746] MC) (NN:[747..754] lineage)))
            (NN:[755..762] disease))
          (NP (-LRB-:[763..764] -LRB-) (NN:[764..769] AHNMD)
              (-RRB-:[769..770] -RRB-)))))
    (.:[770..771] .)))

;sentence 8 Span:772..909
;In some cases,  hematologic parameters are indicative of slowly progressing
;SM although the  clinical course remains indolent over years.
;[829..850]:malignancy:"slowly progressing SM"
(SENT
  (S
    (PP (IN:[772..774] In)
      (NP (DT:[775..779] some) (NNS:[780..785] cases)))
    (,:[785..786] ,)
    (NP-SBJ (JJ:[788..799] hematologic) (NNS:[800..810] parameters))
    (VP (VBP:[811..814] are)
      (ADJP-PRD (JJ:[815..825] indicative)
        (PP (IN:[826..828] of)
          (NP
            (ADJP (RB:[829..835] slowly) (VBG:[836..847] progressing))
            (NN:[848..850] SM))))
      (SBAR-ADV (IN:[851..859] although)
        (S
          (NP-SBJ (DT:[860..863] the) (JJ:[865..873] clinical)
                  (NN:[874..880] course))
          (VP (VBZ:[881..888] remains)
            (ADJP-PRD (JJ:[889..897] indolent))
            (PP-TMP (IN:[898..902] over)
              (NP (NNS:[903..908] years)))))))
    (.:[908..909] .)))

;sentence 9 Span:910..963
;These cases have been referred to  as smouldering SM.
;[948..962]:malignancy:"smouldering SM"
(SENT
  (S
    (NP-SBJ-1 (DT:[910..915] These) (NNS:[916..921] cases))
    (VP (VBP:[922..926] have)
      (VP (VBN:[927..931] been)
        (VP (VBN:[932..940] referred)
          (PP (TO:[941..943] to)
            (NP-1 (-NONE-:[943..943] *)))
          (PP (IN:[945..947] as)
            (NP (VBG:[948..959] smouldering) (NN:[960..962] SM))))))
    (.:[962..963] .)))

;sentence 10 Span:964..1202
;We report on a smouldering patient presenting with typical  skin lesions,
;hypercellular marrow with focal MC aggregates, persistent  leukocytosis
;(20,000-30,000/microl) with eosinophilia (5-10%), marked  lymphadenopathy,
;and splenomegaly.
;[979..990]:malignancy:"smouldering"
;[1024..1036]:malignancy:"skin lesions"
(SENT
  (S
    (NP-SBJ (PRP:[964..966] We))
    (VP (VBP:[967..973] report)
      (PP (IN:[974..976] on)
        (NP
          (NP (DT:[977..978] a) (VBG:[979..990] smouldering)
              (NN:[991..998] patient))
          (VP (VBG:[999..1009] presenting)
            (PP (IN:[1010..1014] with)
              (NP
                (NP (JJ:[1015..1022] typical)
                   (NN:[1024..1028] skin) (NNS:[1029..1036] lesions))
                (,:[1036..1037] ,)
                (NP
                  (NP (JJ:[1038..1051] hypercellular) (NN:[1052..1058] marrow))
                  (PP (IN:[1059..1063] with)
                    (NP (JJ:[1064..1069] focal) (NN:[1070..1072] MC)
                        (NNS:[1073..1083] aggregates))))
                (,:[1083..1084] ,)
                (NP
                  (NP (JJ:[1085..1095] persistent)
                      (NN:[1097..1109] leukocytosis)
                    (PRN (-LRB-:[1110..1111] -LRB-)
                      (NP
                        (NP (CD:[1111..1117] 20,000) (HYPH:[1117..1118] -)
                            (CD:[1118..1124] 30,000))
                        (PP (SYM:[1124..1125] /)
                          (NP (NN:[1125..1131] microl))))
                      (-RRB-:[1131..1132] -RRB-)))
                  (PP (IN:[1133..1137] with)
                    (NP (NN:[1138..1150] eosinophilia)
                      (PRN (-LRB-:[1151..1152] -LRB-)
                        (NP
                          (QP (CD:[1152..1153] 5) (HYPH:[1153..1154] -)
                              (CD:[1154..1156] 10))
                          (NN:[1156..1157] %))
                        (-RRB-:[1157..1158] -RRB-)))))
                (,:[1158..1159] ,)
                (NP (VBN:[1160..1166] marked) (NN:[1168..1183] lymphadenopathy))
                (,:[1183..1184] ,) (CC:[1185..1188] and)
                (NP (NN:[1189..1201] splenomegaly))))))))
    (.:[1201..1202] .)))

;sentence 11 Span:1203..1265
;The C-KIT mutation Asp-816-Val confirmed the  diagnosis of SM.
;[1207..1212]:gene-rna:"C-KIT"
;[1213..1221]:variation-event:"mutation"
;[1222..1225]:variation-state-original:"Asp"
;[1226..1229]:variation-location:"816"
;[1230..1233]:variation-state-altered:"Val"
;[1262..1264]:malignancy:"SM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1203..1206] The) (NN:[1207..1212] C-KIT)
          (NN:[1213..1221] mutation))
      (NP (NN:[1222..1225] Asp) (HYPH:[1225..1226] -) (CD:[1226..1229] 816)
          (HYPH:[1229..1230] -) (NN:[1230..1233] Val)))
    (VP (VBD:[1234..1243] confirmed)
      (NP
        (NP (DT:[1244..1247] the) (NN:[1249..1258] diagnosis))
        (PP (IN:[1259..1261] of)
          (NP (NN:[1262..1264] SM)))))
    (.:[1264..1265] .)))

;sentence 12 Span:1266..1414
;The clinical picture remained stable during an observation  period of 10
;years without signs of progression to an AHNMD or a high grade MC  disease.
;[1380..1385]:malignancy:"AHNMD"
;[1391..1413]:malignancy:"high grade MC  disease"
(SENT
  (S
    (NP-SBJ (DT:[1266..1269] The) (JJ:[1270..1278] clinical)
            (NN:[1279..1286] picture))
    (VP (VBD:[1287..1295] remained)
      (ADJP-PRD (JJ:[1296..1302] stable))
      (PP-TMP (IN:[1303..1309] during)
        (NP
          (NP (DT:[1310..1312] an) (NN:[1313..1324] observation)
              (NN:[1326..1332] period))
          (PP (IN:[1333..1335] of)
            (NP (CD:[1336..1338] 10) (NNS:[1339..1344] years)))))
      (PP (IN:[1345..1352] without)
        (NP
          (NP (NNS:[1353..1358] signs))
          (PP (IN:[1359..1361] of)
            (NP
              (NP (NN:[1362..1373] progression))
              (PP (TO:[1374..1376] to)
                (NP
                  (NP (DT:[1377..1379] an) (NN:[1380..1385] AHNMD))
                  (CC:[1386..1388] or)
                  (NP (DT:[1389..1390] a)
                    
                    (NML (JJ:[1391..1395] high) (NN:[1396..1401] grade))
                    (NN:[1402..1404] MC) (NN:[1406..1413] disease)))))))))
    (.:[1413..1414] .)))

;sentence 13 Span:1415..1591
;These data show that some patients with SM can remain in a clinically 
;indolent smouldering state over years even when presenting with marked 
;eosinophilia and lymphadenopathy.
;[1455..1457]:malignancy:"SM"
(SENT
  (S
    (NP-SBJ (DT:[1415..1420] These) (NNS:[1421..1425] data))
    (VP (VBP:[1426..1430] show)
      (SBAR (IN:[1431..1435] that)
        (S
          (NP-SBJ
            (NP (DT:[1436..1440] some) (NNS:[1441..1449] patients))
            (PP (IN:[1450..1454] with)
              (NP (NN:[1455..1457] SM))))
          (VP (MD:[1458..1461] can)
            (VP (VB:[1462..1468] remain)
              (PP (IN:[1469..1471] in)
                (NP (DT:[1472..1473] a)
                  (ADJP (RB:[1474..1484] clinically) (JJ:[1486..1494] indolent))
                  (VBG:[1495..1506] smouldering) (NN:[1507..1512] state)))
              (PP-TMP (IN:[1513..1517] over)
                (NP (NNS:[1518..1523] years)))
              (SBAR-ADV
                (WHADVP-1 (RB:[1524..1528] even) (WRB:[1529..1533] when))
                (S
                  (NP-SBJ (-NONE-:[1533..1533] *))
                  (VP (VBG:[1534..1544] presenting)
                    (PP (IN:[1545..1549] with)
                      (NP
                        (NP (VBN:[1550..1556] marked)
                            (NN:[1558..1570] eosinophilia))
                        (CC:[1571..1574] and)
                        (NP (NN:[1575..1590] lymphadenopathy))))
                    (ADVP-1 (-NONE-:[1590..1590] *T*))))))))))
    (.:[1590..1591] .)))

;section 14 Span:1595..1640
;PMID: 12007509 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1595..1599] PMID) (::[1599..1600] :) (CD:[1601..1609] 12007509)
        (NN:[1610..1611] -LSB-) (NNP:[1611..1617] PubMed) (::[1618..1619] -)
        (NN:[1620..1627] indexed) (IN:[1628..1631] for)
        (NNP:[1632..1640] MEDLINE-RSB-)))
